National Institutes of Health (NIH)

Full sponsor guidelines are linked here. 
 

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.  Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. 

Full sponsor guidelines are linked here. 

Apply to Internal Competition // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed.

Purpose
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin.

Full sponsor guidelines are linked here. 

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the September 2026 deadline. 

Upcoming Webinar
July 8, 2026, at 1:00 pm (EST).

Please register using the link below to secure your spot.
https://scgcorp.zoom.us/webinar/register/WN_yoQC9j2mSAWyu7HcCxD8Dw#/registration 

Limiting Language
Applicant organizations may submit only one application, provided that the type of instrument does not currently exist in the applicant organization (identified by UEI).

Purpose
This Notice of Funding Opportunity (NOFO) aims to build new research capacity and develop a sustainable research program by supporting the purchase of a single commercially available biomedical research instrument currently unavailable in the institution. Instruments funded through this program must be shared among the users to create new research opportunities, enable reproducible data generation, encourage collaborative research and training, and strengthen long-term research capabilities. The minimum award is $50,000. While there is no limit on the total cost of the instrument, the maximum award is $400,000.

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the July 2026 deadline. 

Per NIH, proposals submitted to the 6/1/2026 SIG deadline should not be resubmitted to the 7/27/2026 deadline. 

Limiting Language
The University of Arizona may submit more than one proposal provided that each application is scientifically distinct. This is an Institutionally Coordinated Submission. 

Purpose
This Notice of Funding Opportunity (NOFO) announces the restructured Shared Instrumentation Grant (SIG) Program that consolidates three existing shared-use instrumentation programs, i.e., the Shared Instrumentation Grant program, the High-End Instrumentation Grant program, and the Basic Instrumentation Grant program. The NOFO invites applications from groups of NIH-supported investigators to purchase or upgrade a single state-of-the-art commercially available instrument or an integrated instrumentation system. The instruments purchased through the SIG Program are required to be optimally shared among the users to ensure efficient and cost-effective research operations, enable rigorous and reproducible measurements, and encourage collaborative research and benefit broad research communities at large. The minimum award is $300,000. There is no cap on the total cost of the instrument; however, the maximum award is $5,000,000.

Apply to Internal Competition // Limit: 2 // Tickets Available: 2

Limiting Language 
Only two applications per institution (identified by Unique Entity Identifier (UEI) number or NIH IPF number) are allowed.

Program Description
Full sponsor guidelines are linked here.

The NIH Director's Early Independence Award helps talented new researchers begin their own independent research program soon after finishing their doctoral degree or clinical training, without first doing postdoctoral training.The award accepts applications on any topic fitting the NIH mission. It is part of the NIH Common Fund's High-Risk, High-Reward Research program.

Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

Requirements

• One PD/PI only: Applications can have only one PD/PI. Multiple PD/PIs are not allowed. Only the PD/PI may be listed as Senior/Key Personnel and submit a biosketch.
• Citizenship: U.S. citizenship is not required. If the PD/PI is not a U.S. citizen, the institution must ensure the visa permit allows them to do the proposed research in the U.S. for the full project period.
• Degree or clinical training dates: The PD/PI must complete their terminal doctoral degree or post-graduate clinical training between May 1, 2025, and September 30, 2027.
  • The date shown on the official transcript is considered the date the degree was completed.
  • Clinical training includes residency and fellowship.
  • At the time of award, either:
    • The PD/PI must have an eligible doctoral degree from an accredited U.S. or foreign institution, oR
    • An authorized official must confirm all degree requirements are complete and the degree will be awarded before September 30, 2027.
• Post-doctoral experience: The PD/PI must not have more than 12 months of postdoctoral training after an earlier, non-terminal doctoral degree. This applies only to individuals with multiple doctoral degrees.
• Effort required:
  • Years 1-2: At least 9.6 person-months per year (80% effort) on the award project
  • Years 3-5:  At least 9.6 person-months per year (80% effort) on independent research overall, including the award project and any other independent research led by the PD/PI.
• Non-independence required: At the time of application, the PD/PI must still be non-independent. All the following must apply:
  • Research direction requires mentor approval
  • Research is mainly supported through another investigator's funding (mentored fellowships, such as an NIH F31/F32 or NSF Graduate Research Fellowship, do not make an applicant ineligible)
  • No institutionally assigned research space
  • Cannot apply for an NIH R01 without a special institutional waiver or exception

The PD/PI may become independent before the award starts and still remain eligible.

• Independent position required: The PD/PI must have a guaranteed, pending independent research position and be able to begin independent research by the project start date.
  • The position does not have to be permanent or tenure-track.
  • The position may depend on receiving this award.
  • The institution must provide substantial support, as described in the application.
  • Moving to a new institution may be advantageous but is not required.
• Career awards: ThePD/PI may apply for both a K award and DP5 simultaneously, but the projects must not overlap scientifically. A PD/PI cannot hold both simultaneously; if awarded the DP5, the K award must be relinquished.
• Site visit: NIH will conduct a site visit near the end of the first year to assess progress and confirm institutional support and independence. If support is insufficient, NIH may take corrective action, including reducing or terminating funding.

The University of Arizona is not eligible to apply for this funding opportunity due to an existing award active through 2030.

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

Purpose
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network. 

The ETCTN LAOs will provide oversight for all scientific, programmatic, financial, and administrative matters related to the sites participating in ETCTN trials as part of their LAOs. ETCTN LAOs are also expected to provide mentorship for investigators who are in the early stages of their research careers with a focus on clinical trials. All ETCTN LAOs will be required to use the ETCTN Pharmacokinetic (PK) Resource Laboratory as a central resource to incorporate PK studies within their early phase clinical trials, when appropriate, to analyze pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, pharmacodynamics, and food effects associated with IND agents being evaluated in ETCTN trials. This PK Laboratory will conduct all pharmacokinetic studies for ETCTN clinical trials involving Investigational New Drug (IND) agents under the regulatory sponsorship of NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).  The ETCTN Pharmacokinetic Resource Laboratory  is funded through a separate award under the NOFO listed below.

• The ETCTN – Network Pharmacokinetic Resource Laboratory under RFA-CA-27-017.

The University of Arizona is not eligible for this funding opportunity

NIGMS will co-fund applications from higher education institutions that award undergraduate (B.S. or B.A.) and/or graduate degrees in biomedical sciences and have received no more than $6 million dollars per year (total costs) from NIH Research Project Grants (RPGs) in each of the preceding two fiscal years, calculated using NIH RePORTER, at the time of the application.  Applications to be considered must support research aligned with the NIGMS mission. Applications for research capacity building in Institutional Development Award (IDeA)-eligible states will be considered.